Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospecti
about
Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis.Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy.
P2860
Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospecti
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@en
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@nl
type
label
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@en
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@nl
prefLabel
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@en
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@nl
P2093
P2860
P921
P1476
Comparison of cetuximab to bev ...... tumor response--a retrospecti
@en
P2093
Cheng-Hwai Tzeng
Chueh-Chuan Yen
Chun-Chi Lin
Hao-Wei Teng
Jen-Kou Lin
Jeng-Kai Jiang
Shung-Haur Yang
Tzu-Chen Lin
Wei-Shone Chen
Yuan-Hao Yang
P2860
P2888
P304
P356
10.1007/S00432-014-1741-0
P577
2014-06-17T00:00:00Z